A.Kh. RAMAZANOVA^1,2, I.G. MUSTAFIN², A.Kh. ODINTSOVA¹, R.M. NABIULLINA², D.T. SIRAZETDINOV¹, D.I. ABDULGANIEVA^1,2

¹Kazan State Medical University, 49 Butlerov Str., Kazan, Russian Federation, 420012

²Republican Clinical Hospital of the MH of RT, 138 Orenburgskiy Trakt, Kazan, Russian Federation, 420064 

Ramazanova A.Kh. — physician of the Department of Gastroenterology, postgraduate student of the Department of Biochemistry, tel. +7-927-404-74-40, e-mail: alsuramazan@mail.ru

Mustafin I.G. — D. Med. Sc., Professor, Head of the Department of Biochemistry, Vice-rector on scientific work, tel. (843) 236-68-82, e-mail: ilshat64@mail.ru

Odintsova A.Kh. — Cand. Med. Sc., Head of the Department of Gastroenterology, tel. (843) 231-21-64, e-mail: odincovaa@yandex.ru

Nabiullina R.M. — Cand. Med. Sc., Assistant of the Department of Biochemistry, tel. (843) 236-68-82, e-mail: nabiullina.rosa@yandex.ru

Sirazetdinov D.T. — Мedical laboratory doctor, tel. (843) 231-21-68, e-mail: alsuramazan@mail.ru

Abdulganieva D.I. — D. Med. Sc., Head of the Department of Hospital Therapy, tel. (843) 231-21-64, e-mail: diana_s@mail.ru

Chronic intestinal inflammation in ulcerative colitis (UC) and Crohn’s disease (CD) initiates the activation of the blood clotting mechanism, inhibits fibrinolysis, disrupts the activity of the natural anticoagulant mechanisms. This article presents pathogenetic aspects of changes in coagulation system and the prevalence of thromboembolic events (TE) in inflammatory bowel disease (IBD). The main risk factors for TE in ulcerative colitis and Crohn’s disease were observed.

Key words: inflammatory bowel disease, thromboembolic complications, hemostasis, Crohn’s disease, ulcerative colitis.

REFERENCES

1. Ivashkin V.T., Shelygin Yu.A., Abdulganieva D.I. et al. The recommendations of the Russian Gastroenterological Association and the Association of Russian Coloproctologists for diagnosis and treatment of adult patients with UC. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2015, no. 1, pp. 48-65 (in Russ.).
2. Tkachev A.V., Mkrschyan L.S., Nikitina K.E. et al. Inflammatory bowel diseases: a. at the crossroads of the problems. Prakticheskaya meditsina, 2012, no. 3 (58), pp. 17-22 (in Russ.).
3. Owczarek D., Cibor D., Głowacki M. et al. Inflammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability. World J. Gastroenterol, 2014, vol. 20, no. 1, pp. 33-63.
4. Yoshida H., Granger D.N. Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation. Inflamm. Bowel Dis, 2009, 15, pp. 1245-1255.
5. Talbot R.W., Heppell J., Dozois R.R., Beart R.W. Jr. Vascular complications of inflammatory bowel disease. Mayo Clin. Proc, 1986, 61, pp. 140-145.
6. Graef V., Baggenstoss A.H., Sauer W.G., Spittel J.A. Jr. Venous thrombosis in non-specific ulcerative colitis. A necropsy study. Arch. Intern. Med, 1965, 117, P. 377-382.
7. Novacek G., Weltermann A., Sobala A., et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology, 2010, 139, P. 779-787.
8. Murthy S.K., Nguyen G.C. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am. J. Gastroenterol, 2011, 106, P. 713-718.
9. Ramazanova A.Kh., Abdulganieva D.I., Odintsova A.Kh. et al. The difficulty of management of patients with inflammatory bowel disease with the presence of thromboembolic complications. Prakticheskaya meditsina, 2013, no. 1-2 (69), pp. 88-91 (in Russ.).
10. Georgia Tsiolakidou, Ioannis-E Koutroubakis Thrombosis and inflammatory bowel disease-the role of genetic risk factors. World J. Gastroenterol, 2008, 14, 28, pp. 4440-4444.
11. Peter D.R. Higgins, Martha Skup, Parvez M. Mulani, Jay Lin, and Jingdong Chao Increased Risk of Venous Thromboembolic Events With Corticosteroid vs Biologic Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2015, 13, pp. 316-321.
12. Jackson L.M., O’Gorman P.J., O’Connell J., et al. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM, 1997, 90, pp. 183-188.
13. Zezos P., Kouklakis G., Saibil F. Inflammatory bowel disease and thromboembolism. World J. Gastroenterol, 2014, vol. 20, no. 38, pp. 13863-13878.
14. Scaldaferri F., Lancellotti S., Pizzoferrato M., et al. Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. World J. Gastroenterol, 2011, 17, pp. 594-608.
15. Bernstein C.N., Sargent M., Vos H.L., et al. Mutations in clotting factors and inflammatory bowel disease. Am. J. Gastroenterol, 2007, 102, pp. 338-343.
16. Yilmaz S., Bayan K., Tüzün Y., et al. A comprehensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: data from Turkey. J. Thromb. Thrombolysis, 2006, 22, pp. 205-212.
17. Solem C.A., Loftus E.V., Tremaine W.J., et al. Venous thromboembolism in inflammatory bowel disease. Am. J. Gastroenterol, 2004, 99, pp. 97-101.
18. Papa A., Danese S., Grillo A., et al. Review article: inherited thrombophilia in inflammatory bowel disease. Am. J. Gastroenterol, 2003, 98, pp. 1247-1251.
19. Saibeni S., Vecchi M., Faioni E.M., et al. Val34Leu factor XIII polymorphism in Italian patients with inflammatory bowel disease. Dig. Liver Dis, 2003, 35, pp. 32-36.
20. Guédon C., Le Cam-Duchez V., Lalaude O., et al. Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. Am. J. Gastroenterol, 2001, 96, pp. 1448-1454.
21. Turri D., Rosselli M., Simioni P., et al. Factor V Leiden and prothrombin gene mutation in inflammatory bowel disease in a Mediterranean area. Dig. Liver Dis, 2001, 33, pp. 559-562.
22. Vecchi M., Sacchi E., Saibeni S., et al. Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis. Dig. Dis. Sci, 2000, 45, pp. 1465-1469.
23. Sundaram K.K., Cotton R., Hart P., et al. Laboratory findings associated with thrombophilia are not more common in inflammatory bowel disease. Clin. Lab. Haematol, 2000, 22, pp. 243-245.
24. Helio T., Wartiovaara U., Halme L., et al. Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease. Scand. J. Gastroenterol, 1999, 34, pp. 170-174.
25. Danese S., Papa A., Saibeni S., et al. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am. J. Gastroenterol, 2007, 102, pp. 174-186.
26. Kuznik B.I. Kletochnye i molekulyarnye mekhanizmy regulyatsii sistemy gemostaza v norme i patologii [Cellular and molecular mechanisms of regulation of the hemostatic system in health and disease]. Chita: Ekspress-izdatel’stvo, 2010. P. 827.
27. Pavlenko V.V., Kataganova G.A., Amirkhanova L.Z. Features of the expression of apoptosis markers in Crohn’s disease. Vestnik Severo-Zapadnogo gosudarstvennogo meditsinskogo universiteta im. I.I. Mechnikova, 2012, no. 3, pp. 37-42 (in Russ.).
28. Wakefield A.J., Sawyerr A.M., Dhillon A.P., et al. Pathogenesis of Crohn’s disease: multifocal gastrointestinal infarction. Lancet, 1989, 2, pp. 1057-1062.
29. Dhillon A.P., Anthony A., Sim R., et al. Mucosal capillary thrombi in rectal biopsies. Histopathology, 1992, 21, pp. 127-133.
30. Scaldaferri F., Lancellotti S., Pizzoferrato M., De Cristofaro R. Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. World J. Gastroenterol, 2011, vol. 17, pp. 594-608.
31. Chande N., McDonald J.W., Macdonald J.K. et al. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev, 2010, no. 6 (10).
32. Tan V.P., Chung A., Yan B.P., Gibson P.R. Venous and arterial disease in inflammatory bowel disease. J. Gastroenterol. Hepatol, 2013, 28, pp. 1095-1113.
33. Van Assche G., Dignass A., Bokemeyer B., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J. Crohns Colitis, 2013, 7, pp. 1-33.